ANNEXU.K.

In Annex XVII to Regulation (EC) No 1907/2006, the following entry is added:

68.Perfluorooctanoic acid (PFOA)

CAS No 335-67-1

EC No 206-397-9

and its salts.

Any related substance (including its salts and polymers) having a linear or branched perfluoroheptyl group with the formula C7F15- directly attached to another carbon atom, as one of the structural elements.

Any related substance (including its salts and polymers) having a linear or branched perfluorooctyl group with the formula C8F17- as one of the structural elements.

The following substances are excluded from this designation:

  • C8F17-X, where X = F, Cl, Br.

  • C8F17-C(=O)OH, C8F17-C(=O)O-X′ or C8F17-CF2-X′ (where X′ = any group, including salts).

1.Shall not be manufactured, or placed on the market as substances on their own from 4 July 2020.

2.Shall not, from 4 July 2020, be used in the production of, or placed on the market in:

(a)

another substance, as a constituent;

(b)

a mixture;

(c)

an article,

in a concentration equal to or above 25 ppb of PFOA including its salts or 1 000 ppb of one or a combination of PFOA-related substances.

3.Points 1 and 2 shall apply from:

(a)

4 July 2022 to:

(i)

equipment used to manufacture semi-conductors;

(ii)

latex printing inks.

(b)

4 July 2023 to:

(i)

textiles for the protection of workers from risks to their health and safety;

(ii)

membranes intended for use in medical textiles, filtration in water treatment, production processes and effluent treatment;

(iii)

plasma nano-coatings.

(c)

4 July 2032 to medical devices other than implantable medical devices within the scope of Directive 93/42/EEC.

4.Points 1 and 2 shall not apply to any of the following:

(a)

perfluorooctane sulfonic acid and its derivatives, which are listed in Part A of Annex I to Regulation (EC) No 850/2004;

(b)

the manufacture of a substance where this occurs as an unavoidable by-product of the manufacture of fluorochemicals with a carbon chain equal to or shorter than 6 atoms;

(c)

a substance that is to be used, or is used as a transported isolated intermediate, provided that the conditions in points (a) to (f) of Article 18(4) of this Regulation are met;

(d)

a substance, constituent of another substance or mixture that is to be used, or is used:

(i)

in the production of implantable medical devices within the scope of Directive 93/42/EEC;

(ii)

in photographic coatings applied to films, papers or printing plates;

(iii)

in photo-lithography processes for semiconductors or in etching processes for compound semiconductors;

(e)

concentrated fire-fighting foam mixtures that were placed on the market before 4 July 2020 and are to be used, or are used in the production of other fire-fighting foam mixtures.